Boston Scientific (NYSE:BSX) Director Sells $1,266,927.48 in Stock

Boston Scientific Corporation (NYSE:BSX) Director Ellen Zane sold 12,891 shares of the company’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the transaction, the director directly owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Boston Scientific Price Performance

BSX traded up $0.10 during trading on Thursday, reaching $99.00. 6,809,356 shares of the stock were exchanged, compared to its average volume of 7,974,178. The business’s 50 day moving average price is $100.34 and its two-hundred day moving average price is $102.43. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.37 and a quick ratio of 0.82. The company has a market capitalization of $146.69 billion, a price-to-earnings ratio of 52.94, a P/E/G ratio of 2.02 and a beta of 0.58. Boston Scientific Corporation has a 1 year low of $85.98 and a 1 year high of $109.50.

Boston Scientific (NYSE:BSX) last posted its earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The company had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.Boston Scientific’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same period in the previous year, the business earned $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. As a group, equities research analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Institutional Trading of Boston Scientific

Hedge funds have recently added to or reduced their stakes in the business. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter worth about $25,000. Financial Consulate Inc. acquired a new stake in Boston Scientific in the 3rd quarter worth about $25,000. 1248 Management LLC acquired a new stake in Boston Scientific in the 1st quarter worth about $26,000. FWL Investment Management LLC acquired a new stake in Boston Scientific in the 2nd quarter worth about $26,000. Finally, Y.D. More Investments Ltd acquired a new stake in Boston Scientific in the 1st quarter worth about $27,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have commented on the company. Royal Bank Of Canada reiterated an “outperform” rating and set a $125.00 target price on shares of Boston Scientific in a research report on Monday, September 29th. Erste Group Bank downgraded Boston Scientific from a “buy” rating to a “hold” rating in a research report on Friday, October 3rd. Robert W. Baird lifted their price objective on Boston Scientific from $123.00 to $128.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 1st. Jefferies Financial Group restated a “hold” rating on shares of Boston Scientific in a research report on Monday, July 21st. Finally, Canaccord Genuity Group restated a “buy” rating and set a $132.00 price objective on shares of Boston Scientific in a research report on Thursday, October 23rd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and two have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $123.77.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.